149 results about "Tumor stem cell" patented technology

The invention provides a circulating tumor stem cell detection kit based on magnetic beads and a microfluidic chip. The circulating tumor stem cell detection kit is characterized by comprising a microfluidic chip, at least one immunomagnetic bead, and at least one fluorescent antibody against a tumor stem cell biomarker, wherein the immunomagnetic bead can be specifically bonded with the circulating tumor stem cell and marked with the tumor stem cell biomarker; the microfluidic chip comprises a glass chip base; a microfluidic channel is arranged on the glass chip base; a soft magnetic micro-array is arranged inside the microfluidic channel. By adopting the circulating tumor stem cell detection kit, a plurality of different categories of rare circulating tumor stem cells can be captured and detected by sampling once, and the circulating tumor stem cell detection kit has high sensitivity and specificity, is convenient and fast to operate, can easily collect captured cells, and does not need complicated surface modification processes of a first antibody and a second antibody of the microfluidic channel inside the chip.

This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided.

The invention discloses a cell culture medium. The raw material formula of the cell culture medium comprises 33.33ml of DMEM/High Glucose (DMEM high-glucose culture medium), 66.67ml of HAM'S/F-12 culture medium, 3-5mg/mL of plant-origin recombinant human serum albumin, 100U/ml of penicillin, 100 micrograms/milliliter of streptomycin, 2.5 micrograms/milliliter of amphotericin B, 0.2-0.5 micrograms/milliliter of hydrocortisone, 3-6 micrograms/milliliter of insulin, 6-10ng/ml of cholera toxin B, 9-12ng/ml of human epidermal growth factor EGF, 22-25 micrograms/milliliter of adenine, and 7-9 micromoles/liter of Y-27632. The cell culture medium can be used for culturing primary human tumor cells or tumor stem cells. The cell culture medium is improved; when the cell culture medium is applied to culturing the primary human tumor cells or the tumor stem cells, the cell culture medium is capable of better accelerating the growth of the primary tumor cells and obtaining the human tumor stem cells of a higher ratio.

The invention belongs to the technical field of modern biotechnology cell culture. A purpose of the invention is to provide a tumor stem cell suspension culture method, which can be used for culture of tumor cells with different tissue sources, and tumor stem cells obtained through the culture method have characteristics of self-renewal capacity and enrichment. The tumor stem cell suspension culture method comprises: carrying out digestion centrifugation collection on tumor cells requiring culture, adopting PBS to carry out resuspending centrifugation, adding to a prepared suspension culture medium of the invention, carrying out beating-up into a single cell suspension, inoculating into a paved ultra-low absorption culture dish, and carrying out cell culture. The tumor stem cell suspension culture method has the following characteristics that: ball forming rates of various in vitro cultured tumor cells are high, multi-function factors are expressed, the OCT4 proportion and the NANOG proportion are increased, rich and comprehensive experimental materials are provided for tumor stem cell researches, and broad application prospects are provided in basic researches and clinical applications.

The invention discloses a method for in-vitro amplification of tumor stem cells. The method comprises the following steps of carrying out in-vitro three-dimensional culture on tumor cells by an alginate gel support, and adjusting and controlling the rigidity of the alginate gel support by a change of support preparation parameters such as alginate molecular weight, a ratio (GM) of guluronic acid content to mannuronic acid content, a calcium ion concentration and calcification time, so that hardness of an in-vitro matrix in different tumor tissue microenvironments is simulated and in-vitro amplification of tumor stem cells in different tissue is realized. The method can be operated simply, has a low cost and controllable performances, can be industrialized and is a good method for in-vitro amplification on tumor stem cells having different sources.

The invention discloses an anti-hepatoma stem cell monoclonal antibody which is secreted by a mouse hybridoma cell 4P-120 with the collection number of CGMCC No.8800. Proven by experiments, the monoclonal antibody can be specifically combined with hepatoma cells and is capable of specifically recognizing hepatoma tissues, antigens recognized by the monoclonal antibody are highly expressed in cancer tissues of human hepatoma, but are not expressed or slightly expressed in para-carcinoma tissues, and positive-to-negative differentiation and negative-to-positive defifferentiation exist in a cell multiplication process. Compared with cells with low antigen expression, cells with high antigen expression have higher proliferation capability, clone formation capability, balling capability, scratch transfer capability and invasion transfer capability; and the invention provides a functional monoclonal antibody with an application prospect for treating hepatoma with targeted tumor stem cells, and the monoclonal antibody can be used for preparing medicines for treating hepatoma.

The invention provides an application of chlorogenic acid and/or a chlorogenic acid derivative in a tumor stem cell treatment drug and belongs to the technical field of medicine. According to the application of the chlorogenic acid and/or the chlorogenic acid derivative in the tumor stem cell treatment drug, the new application of the chlorogenic acid is provided, and the chlorogenic acid is applied to the tumor stem cell treatment drug, so that the tumor stem cells can be inhibited and killed by the drug and relapse, metastasis and multidrug resistance of tumors are effectively prevented.

The invention belongs to the field of medicine, and particularly relates to the application of 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol to the preparation of an anti-tumor drug. A great number of experiments show that the 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol has the remarkable effect of suppressing malignant tumors such as malignant mammary tumor cells, lymphoma cells and encephaloma cells, and particularly has the effect of killing drug-resistant tumor stem cells such as encephaloma stem cells, so that the 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol can be used for the preparation of the anti-tumor drug, and the drug contains 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol of effective content and a pharmaceutically acceptable carrier.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. In one embodiment, the method is administered in combination with localized internal ionizing radiation therapy.

The invention relates to dendritic cell (DC) tumor vaccine in which a multi-medicine resistance tumor stem cell antigen composition is loaded. The antigen composition loaded in the DC tumor vaccine derives from tumor tissues, and is mainly used for tumor stem cells; and specifically, the tumor tissues are subjected to tumor stem cell primary separation and culture so as to obtain the tumor stem cells, the tumor stem cells are screened by a flow cytometry so as to obtain tumor stem cells with multi-medicine resistance, and finally full cell antigens are prepared.

Provided herein is a method for diagnosing/prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

The invention provides a dendritic cell carried by a tumor stem cell antigen and subjected to tolerance screening and a preparation method thereof, application of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening in preparing anti-tumor medicament, a kit for preparing the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening, and a vaccine comprising the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening. The dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening and the medicament prepared by an immune composition of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening can kill tumor stem cells causing tumor relapse in vivo and in vitro so as to provide possibility for overcoming the tumor tolerance and radically treating the relapse and transfer of tumor.

The present invention relates to a new medical use of fenretinide or bioactive derivatives thereof, particularly to the use of fenretinide or bioactive derivatives thereof in the preparation of a medicament for eliminating or killing tumor stem cells in a subject or for treating and/or preventing a tumor disease originating from tumor stem cells in a subject. The invention further relates to a new use of fenretinide or bioactive derivatives thereof in combination with other anti-tumor agents, a pharmaceutical composition comprising said fenretinide or bioactive derivatives thereof and at least one additional anti-tumor agent, a method of screening said other anti-tumor agent, a method of eliminating or killing tumor stem cells or particularly hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof, as well as a method of eliminating or killing tumor stem cells and tumor cells derived from tumor stem cells, particularly hematologic tumor stem cells and hematologic tumor cells derived from hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof in combination with other anti-tumor agent(s).

The invention discloses a binding protein of a tumor stem cell marker molecule EpCAM and application of the binding protein. The binding protein is a binding protein formed by one or a combination ofat least two of an NB85 binding protein, an NB143 binding protein, an NB278 binding protein, an NB431 binding protein and an NB589 binding protein. The five binding proteins have the amino acid sequences as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 respectively. The invention also discloses the application of the binding protein of the tumor stem cell marker molecule EpCAM in preparation of antitumor drugs. The binding protein provided by the invention is high in structural stability, easy to modify and human-derived, has no immunogenicity in a human body, andcan be better applied to the development of the antitumor drugs.

The invention discloses a magnetic bead immunodetection kit for human colorectal cancer tumor stem cell markers CD44 and CD133, and belongs to the field of immunoglobulin. The kit comprises a Solution I, protease K, a fluorescent CD44 antibody and a magnetic bead CD133 antibody. Technology combining magnetic beads and fluorescence radiation is adopted in the kit for detecting CD44 and CD133 on cytomembranes, thereby saving tedious operation of a flow cytometry. A small quantity of a pathological sample of a patient is added in a kit with the magnetic bead antibody and the fluorescent antibody well prepared and is detected through a fluorescence microscope to get a result. The kit is simple to use, short in detection time and low in cost and has bright application prospects.

The invention discloses a separation method of cancer stem cells. Cancer stem cells and differentiated tumor cells can be separated by different mitochondrial membrane potential of different cells. The cell subgroup with high mitochondrial membrane potential is rich in cancer stem cells, and the cell subgroup with low mitochondrial membrane potential is rich in differentiated tumor cells.